Shuttle Pharmaceuticals Secures $5.75 Million in New Funding
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) has announced a significant milestone in its growth journey by successfully completing a public offering of its common stock. This offering, valued at $5.75 million, consists of 19,166,667 shares at a price of $0.30 per share. The company intends to utilize these funds strategically to enhance its clinical and operational capacities.
Purpose of the Funding
The primary aim of this funding is to bolster Shuttle Pharma's initiatives, particularly focusing on their Phase II clinical trial of their leading product candidate. This trial is critical as it seeks to better the efficacy of radiation therapy treatments for cancer patients.
Expanding Clinical Trials
In addition to financing the clinical trial, Shuttle Pharma plans to channel resources toward marketing and advertising strategies. This investment aims to raise awareness about their innovative therapies that are designed to enhance the lives of cancer patients undergoing radiation therapy.
Financial Details
The public offering was executed on a firm commitment basis with WestPark Capital, Inc. acting as the Sole Book-Runner. The gross proceeds from the offering will help cover underwriting fees, commissions, and other costs associated with the transaction, ensuring effective utilization of resources to maximize clinical outcomes.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty of the Georgetown University Medical Center, Shuttle Pharmaceuticals stands at the forefront of developing specialty pharmaceuticals. Their innovative approach focuses on developing drugs that improve the efficacy of radiation therapy, while minimizing the side effects that cancer treatments often impose on patients.
Mission and Vision
The mission of Shuttle Pharma is to enhance the quality of life for cancer patients by creating therapies that promote higher cure rates and longer survivability. By leveraging advancements in radiation sensitivity, they aspire to offer solutions that work synergistically with existing treatment methods such as surgery, chemotherapy, and immunotherapy.
Continued Commitment to Innovation
As Shuttle Pharmaceutical moves forward with its clinical endeavors, the team remains deeply focused on the research and development of their therapies. The goal is not just to treat cancer, but to transform the experience of cancer patients throughout their treatment journey.
Looking Ahead
The path ahead for Shuttle Pharmaceuticals is filled with ambitious plans aimed at scaling their impact in the oncology space. With the recent funding, the company is well-positioned to advance their clinical trials and expand their reach.
Frequently Asked Questions
What is the main purpose of the recent funding announcement?
The funding aims to support Shuttle Pharma's Phase II clinical trial and enhance marketing efforts.
How many shares were offered in the public offering?
The public offering consisted of 19,166,667 shares of common stock.
Who acted as the Sole Book-Runner for the offering?
WestPark Capital, Inc. served as the Sole Book-Runner for the offering.
What is Shuttle Pharmaceuticals' focus?
Shuttle Pharmaceuticals specializes in developing therapies that improve outcomes for cancer patients undergoing radiation therapy.
When was Shuttle Pharmaceuticals founded?
Shuttle Pharmaceuticals was founded in 2012 by faculty members of the Georgetown University Medical Center.
